Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
A Randomized, Open Label, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of AD-102 in Healthy Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Korea University Guro Hosptial
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2 at the time of screening visit
- The Age between 19 and 50 in healthy male volunteers at the time of screening visit
Exclusion Criteria:
- As a result of laboratory tests, the following figures: ALT or AST> 2 times upper limit of normal range
- As a result of laboratory tests, the following figures: 25-OH vitamin D total <9 ng/mL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Raloxifene 60mg/Cholecalciferol 800IU to AD-102
Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
|
Raloxifene 60mg/Cholecalciferol 800IU tablet
AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
|
|
Experimental: AD-102 to Raloxifene 60mg/Cholecalciferol 800IU
Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
|
Raloxifene 60mg/Cholecalciferol 800IU tablet
AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Plasma Concentration (Cmax)
Time Frame: pre-dose to 96 hours
|
Cmax of Raloxifene
|
pre-dose to 96 hours
|
|
Peak Plasma Concentration (Cmax)
Time Frame: pre-dose to 72 hours
|
Cmax of corrected Cholecalciferol
|
pre-dose to 72 hours
|
|
Area under the curve in time plot (AUCt)
Time Frame: pre-dose to 96 hours
|
AUCt of Raloxifene
|
pre-dose to 96 hours
|
|
Area under the curve in time plot (AUCt)
Time Frame: pre-dose to 72 hours
|
AUCt of corrected Cholecalciferol
|
pre-dose to 72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the curve in time plot (AUCinf)
Time Frame: pre-dose to 96 hours
|
AUCinf of Raloxifene
|
pre-dose to 96 hours
|
|
Area under the curve in time plot (AUCinf)
Time Frame: pre-dose to 72 hours
|
AUCinf of Corrected Cholecalciferol
|
pre-dose to 72 hours
|
|
Time to reach Cmax
Time Frame: pre-dose to 96 hours
|
Tmax of Raloxifene
|
pre-dose to 96 hours
|
|
Time to reach Cmax
Time Frame: pre-dose to 72 hours
|
Tmax of Corrected Cholecalciferol
|
pre-dose to 72 hours
|
|
Effective half-life
Time Frame: pre-dose to 96 hours
|
t1/2 of Raloxifene
|
pre-dose to 96 hours
|
|
Effective half-life
Time Frame: pre-dose to 72 hours
|
t1/2 of Corrected Cholecalciferol
|
pre-dose to 72 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with adverse events
Time Frame: From Day 1 until 32 Days
|
Incidence rate of adverse events
|
From Day 1 until 32 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Osteoporosis
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Micronutrients
- Hormone Antagonists
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Vitamin D
- Cholecalciferol
- Raloxifene Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- AD-102BE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.